Akeso Cadonilimab Combo Delivers Strong NSCLC Trial Results
Hong Kong, April 6, 2026 Promising Results in Immunotherapy-Resistant NSCLC In a significant advancement for lung cancer immunotherapy, Akeso,...
Combination Therapy
Advertisement
Novocure PANOVA-4 Trial Shows Positive Cancer Results
Baar, Switzerland – March 2026 Novocure announced positive topline results from its Phase 2 PANOVA-4 clinical trial evaluating Tumor...
Tau Immunotherapy AADvac1 Enters Landmark AD Trial
SAN FRANCISCO, Calif., Feb. 4, 2026 — Axon Neuroscience announced that its active tau immunotherapy AADvac1 has been selected...
Sagimet Advances MASH Combination Therapy With Phase 1 PK Data
SAN MATEO, Calif., Dec. 18, 2025 — Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company focused on metabolic and fibrotic...
Paxalisib Boosts Anti-Tumor Immunity in Advanced Breast Cancer
SYDNEY, Dec. 10, 2025 — Kazia Therapeutics Limited (NASDAQ: KZIA) unveiled compelling clinical and translational data highlighting the ability...
Advertisements
FDA Approves Jazz Pharma’s Zepzelca + Tecentriq Combo for ES-SCLC
DUBLIN, Oct. 2, 2025 – Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that the U.S. Food and Drug Administration...
SystImmune Showcases Pivotal ADC Data at ESMO 2025, Strengthening Next-Generation Cancer Pipeline
REDMOND, Wash., Sept. 24, 2025 – SystImmune, Inc. announced the upcoming presentation of new clinical data on izalontamab brengitecan...
FDA Clears WIDAPLIK™, Developed with Piramal Pharma Solutions
Piramal Pharma Solutions, a global contract development and manufacturing organization (CDMO), has collaborated with George Medicines to develop WIDAPLIK™,...
Advertisement
